Phase 2 Leukaemia Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older
• People diagnosed with a blood/bone marrow condition called MDS (myelodysplastic syndrome) or CMML (chronic myelomonocytic leukaemia) or MDS/MPN (a related overlap condition), confirmed using standard medical classification — with eligibility depending on which of the following groups applies:
  • Group A: MDS with a higher-risk score (IPSS-R above 3.5) and more than 5% abnormal cells (blasts), where a standard type of treatment (HMA therapy) did not work after 6 cycles, or the condition came back or got worse at any point
  • Group B: CMML (type 1 or 2) where HMA therapy did not work after 6 cycles, or the condition came back or got worse at any point
  • Group C: MDS with a higher-risk score (IPSS-R above 3.5) and 10% or more abnormal cells, with no prior HMA treatment
  • Group D: CMML type 2, or CMML type 1 with at least one higher-risk feature such as disease outside the bone marrow, an enlarged spleen, low platelets, low haemoglobin, high white blood cell count, certain chromosome changes, or specific high-risk gene mutations — with no prior HMA treatment
  • Group E: A related overlap blood condition (MDS/MPN) with more than 5% abnormal cells, where HMA therapy did not work after 6 cycles, or the condition came back or got worse at any point
  • Group F: Certain MDS/MPN overlap conditions with no prior HMA treatment, where there are 10% or more abnormal cells, or more than 5% abnormal cells alongside higher-risk features (such as enlarged spleen, high white cell count, or specific genetic changes), or where HMA therapy is considered unlikely to help due to the nature of the disease
• People with a general health/functioning score of 2 or less on a standard medical scale (ECOG), meaning able to carry out basic self-care even if not able to do all physical activity
• People with kidneys working well enough (a clearance rate above 30 ml/min, as measured by a standard formula)
• People with liver function within acceptable ranges for this trial (confirm with trial site for specific values)
• People willing to follow all the rules and restrictions set out in the trial plan
• People who have read and signed a consent form showing they understand what the trial involves and agree to take part
• Both English-speaking and non-English-speaking people are eligible to participate

Who may not be able to join:

• People with an active infection that is not responding adequately to antibiotic treatment
• People with serious heart failure (classified as NYHA Class III or IV) or a heart pumping function below 50% on a heart scan
• People who have had a heart attack in the past 6 months, or who have unstable or uncontrolled chest pain (angina), or a history of severe or uncontrolled irregular heart rhythms
• People who are currently pregnant or breastfeeding
• People who are capable of having children but are unwilling to use reliable contraception throughout the trial (specific contraception methods are listed in the trial protocol — confirm with trial site)
• People who are capable of becoming pregnant but do not have a negative pregnancy test result (urine or blood test) at the start of the trial screening process
• People currently receiving another experimental treatment, or any other chemotherapy, radiation therapy, or immunotherapy at the same time as this trial

Important: Always verify eligibility with the trial site directly before applying.